Carsten Thiel

Leader in
Scientific Marketing

Carsten Thiel’s career within the realm of biomedicine, pharmaceutical marketing, and the medical sector spans many years, and touches upon various disciplines related to the field. This myriad of experiences, combined, has allowed Thiel to flourish within his field, and to become a leader in scientific marketing.

Born in Berlin, Thiel’s family lineage was rich with medical professionals, including his medic mother and father. Enthralled with DNA, and the concept of a pre-written manifest destiny for each individual, Thiel excelled throughout his education, setting the undoubtable path to remain within a not-yet-decided aspect of the medical field. Thiel initially pursued studies in Chemistry in his native country’s Malbrook, before exploring an Anglo-Saxon educational experience within the United Kingdom’s University of Bristol. Focused on the study of biochemistry, Thiel earned his Bachelor of Science degree, and forged ahead into post-undergraduate education.

Carsten Thiel attended the prestigious Max Planck Institute For Biophysical Chemistry, an elite research organization in Germany. Specializing in molecular biology, Thiel studied proteins involved in the morphing of healthy cells into cancerous cells. Thiel earned his PhD, and entered the workforce post-matriculation via the highly innovative pharmaceutical giant Hoffman la-Roche.

Early within his career as a Communications and Product Manager, Thiel parlayed his knowledge of scientific marketing, consumer culture, medical insight, and patient-first code of ethics into a swiftly rising career. Less than a year later, Thiel was provided with the vastly important duty of spearheading the initial product launch of the company’s first foray into the weight-loss sector, via new product Xenical. Thiel’s expertise, leadership style, and knowledge created a stellar initial launch for the product, with first year sales surpassing one billion Swiss francs. Most importantly, however, the product was well received within the mass market, and retained a positive consumer reputation.

After his initial foray into launching new products, Thiel excelled within this role throughout several years, launching many breakthrough innovations throughout various niche fields of the medical sector. Believing in the credo that these new treatments would assist thousands of patients, Thiel continuously sought ways to provide meaningful aid to all individuals through training prescribers, and ensuring unparallelled quality control standards.


Press

Carsten Thiel: Impactful Medicine

Carsten Thiel: Impactful Medicine – Medical Daily Times

As a visionary within the realm of biotechnology, Carsten Thiel’s leadership, expertise, and professional experience has been parlayed into the successful launch of various high-profile medical products, such as Strensiq, Prolia, Vectibix and Neulasta. Not only has he spearheaded the market launch of many medical breakthrough therapies, but his direct involvement has improved the lives of thousands of patients.

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

HEMEL HEMPSTED, England and BOSTON, May 15, 2019 /PRNewswire/ — EUSA Pharma (EUSA), a global biopharmaceutical company focused on oncology and rare disease,…

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development | Markets Insider

HEMEL HEMPSTED, England and BOSTON, May 15, 2019 /PRNewswire/ — EUSA Pharma (EUSA), a global biopharmaceutical company focused on oncology and rare disease, today announced the strengthening of its senior leadership team with the appointments of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development.

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

HEMEL HEMPSTED, England and BOSTON, May 15, 2019 /PRNewswire/ — EUSA Pharma (EUSA), a global biopharmaceutical company focused on oncology and rare disease, today announced the strengthening of its senior leadership team with the appointments of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development.

SEE MORE >